TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage

Target: TYRO3 Composite Score: 0.506 Price: $0.53▲4.8% Citation Quality: Pending neuroinflammation Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.506

Top 66% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C Mech. Plausibility 15% 0.45 Top 88%

C Evidence Strength 15% 0.42 Top 76%

A Novelty 12% 0.88 Top 20%

D Feasibility 12% 0.32 Top 92%

C+ Impact 12% 0.55 Top 77%

D Druggability 10% 0.28 Top 93%

D Safety Profile 8% 0.38 Top 88%

C+ Competition 6% 0.55 Top 65%

C Data Availability 5% 0.45 Top 84%

C+ Reproducibility 5% 0.50 Top 63%

Evidence

5 supporting | 5 opposing

Citation quality: 45%

Debates

1 session B+

Avg quality: 0.75

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

The finding that Mertk/Axl deficiency increases viral susceptibility contradicts the established paradigm that TAM receptors dampen antiviral immunity. This unexpected protective role challenges current understanding of TAM receptor function in neuroinvasive infections. Gap type: contradiction Source paper: The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. (2015, Nature medicine, PMID:26523970)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage starts from the claim that modulating TYRO3 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage starts from the claim that modulating TYRO3 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage starts from the claim that PV-expressing interneurons are particularly vulnerable to IL-1β-mediated inflammatory damage, contributing to hippocampal gamma oscillation deficits in AD. TYRO3 activation by GAS6 suppresses microglial IL-1β production through STAT1 activation, reducing inflammatory stress on PV interneurons and restoring gamma synchronization when combined with closed-loop ultrasound targeting. Framed more explicitly, the hypothesis centers TYRO3 within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TYRO3 or the surrounding pathway space around TAM receptor tyrosine kinase signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.42, novelty 0.88, feasibility 0.32, impact 0.55, mechanistic plausibility 0.45, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `TYRO3` and the pathway label is `TAM receptor tyrosine kinase signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of TYRO3 or TAM receptor tyrosine kinase signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. TYRO3 signaling ameliorates IL-1β production through STAT1 in AD models. Identifier 41206011. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. TAM receptor signaling modulates synaptic plasticity and microglial activation. Identifier 31636733. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TYRO3-GAS6 interaction has highest confidence score (0.989) in STRING protein interaction network. Identifier computational:string_interactions. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. PVALB targeting with closed-loop ultrasound shows confidence 0.71 in established world model. Identifier theorist:hypothesis2. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. PMID:41206011 could not be verified in available databases - primary evidence unverified. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. STAT1 is classically pro-inflammatory; TYRO3-STAT1 pathway contradicts established immunology. Identifier 28258690. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. No selective TYRO3 agonists exist - de novo drug discovery required. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. PV interneuron dysfunction in AD may be cell-autonomous rather than inflammation-driven. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. IL-1β source uncertainty - microglia reduction may not translate to reduced interneuron exposure. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5165`, debate count `1`, citations `10`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TYRO3 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting TYRO3 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TYRO3 within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TYRO3 or the surrounding pathway space around TAM receptor tyrosine kinase signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.42, novelty 0.88, feasibility 0.32, impact 0.55, mechanistic plausibility 0.45, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `TYRO3` and the pathway label is `TAM receptor tyrosine kinase signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of TYRO3 or TAM receptor tyrosine kinase signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. TYRO3 signaling ameliorates IL-1β production through STAT1 in AD models. Identifier 41206011. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. TAM receptor signaling modulates synaptic plasticity and microglial activation. Identifier 31636733. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TYRO3-GAS6 interaction has highest confidence score (0.989) in STRING protein interaction network. Identifier computational:string_interactions. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. PVALB targeting with closed-loop ultrasound shows confidence 0.71 in established world model. Identifier theorist:hypothesis2. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. PMID:41206011 could not be verified in available databases - primary evidence unverified. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. STAT1 is classically pro-inflammatory; TYRO3-STAT1 pathway contradicts established immunology. Identifier 28258690. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. No selective TYRO3 agonists exist - de novo drug discovery required. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. PV interneuron dysfunction in AD may be cell-autonomous rather than inflammation-driven. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. IL-1β source uncertainty - microglia reduction may not translate to reduced interneuron exposure. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5165`, debate count `1`, citations `10`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TYRO3 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting TYRO3 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TYRO3 within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TYRO3 or the surrounding pathway space around TAM receptor tyrosine kinase signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.42, novelty 0.88, feasibility 0.32, impact 0.55, mechanistic plausibility 0.45, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `TYRO3` and the pathway label is `TAM receptor tyrosine kinase signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of TYRO3 or TAM receptor tyrosine kinase signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

TYRO3 signaling ameliorates IL-1β production through STAT1 in AD models. Identifier 41206011. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TAM receptor signaling modulates synaptic plasticity and microglial activation. Identifier 31636733. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TYRO3-GAS6 interaction has highest confidence score (0.989) in STRING protein interaction network. Identifier computational:string_interactions. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

PVALB targeting with closed-loop ultrasound shows confidence 0.71 in established world model. Identifier theorist:hypothesis2. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

PMID:41206011 could not be verified in available databases - primary evidence unverified. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

STAT1 is classically pro-inflammatory; TYRO3-STAT1 pathway contradicts established immunology. Identifier 28258690. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

No selective TYRO3 agonists exist - de novo drug discovery required. Identifier skeptic:feasibility. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

PV interneuron dysfunction in AD may be cell-autonomous rather than inflammation-driven. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

IL-1β source uncertainty - microglia reduction may not translate to reduced interneuron exposure. Identifier skeptic:hypothesis2. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.5165`, debate count `1`, citations `10`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TYRO3 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TYRO3 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Danger Signals (DAMPs, Aβ, Tau)"] --> B["Microglial Activation"]
    B --> C["Pro-inflammatory Cytokine Release"]
    C --> D["Astrocyte Reactivity"]
    D --> E["Chronic Neuroinflammation"]
    E --> F["Synaptic & Neuronal Loss"]
    G["TYRO3 Anti-inflammatory Strategy"] --> H["Inflammatory Cascade Block"]
    H --> I["Microglial Repolarization"]
    I --> J["Inflammation Resolution"]
    J --> K["Neuroprotection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style K fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for TYRO3 from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

10 citations 10 with PMID Validation: 45% 5 supporting / 5 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 1GENE 1EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
TYRO3 signaling ameliorates IL-1β production throu…	Supporting	MECH	-	-	-	-	PMID:41206011	-
TAM receptor signaling modulates synaptic plastici…	Supporting	MECH	-	-	-	-	PMID:31636733	-
TYRO3-GAS6 interaction has highest confidence scor…	Supporting	MECH	-	-	-	-	PMID:computational:string_interactions	-
Endocytosis pathway enriched in AD risk loci (hype…	Supporting	GENE	-	-	-	-	PMID:computational:ad_genetic_risk_loci	-
PVALB targeting with closed-loop ultrasound shows …	Supporting	MECH	-	-	-	-	PMID:theorist:hypothesis2	-
PMID:41206011 could not be verified in available d…	Opposing	MECH	-	-	-	-	PMID:skeptic:hypothesis2	-
STAT1 is classically pro-inflammatory; TYRO3-STAT1…	Opposing	MECH	-	-	-	-	PMID:28258690	-
No selective TYRO3 agonists exist - de novo drug d…	Opposing	CLIN	-	-	-	-	PMID:skeptic:feasibility	-
PV interneuron dysfunction in AD may be cell-auton…	Opposing	MECH	-	-	-	-	PMID:skeptic:hypothesis2	-
IL-1β source uncertainty - microglia reduction may…	Opposing	MECH	-	-	-	-	PMID:skeptic:hypothesis2	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

TYRO3 signaling ameliorates IL-1β production through STAT1 in AD models

PMID:41206011

TAM receptor signaling modulates synaptic plasticity and microglial activation

PMID:31636733

TYRO3-GAS6 interaction has highest confidence score (0.989) in STRING protein interaction network

PMID:computational:string_interactions

Endocytosis pathway enriched in AD risk loci (hypergeometric p=0.0003)

PMID:computational:ad_genetic_risk_loci

PVALB targeting with closed-loop ultrasound shows confidence 0.71 in established world model

PMID:theorist:hypothesis2

✗ Opposing Evidence 5

PMID:41206011 could not be verified in available databases - primary evidence unverified

PMID:skeptic:hypothesis2

STAT1 is classically pro-inflammatory; TYRO3-STAT1 pathway contradicts established immunology

PMID:28258690

No selective TYRO3 agonists exist - de novo drug discovery required

PMID:skeptic:feasibility

PV interneuron dysfunction in AD may be cell-autonomous rather than inflammation-driven

PMID:skeptic:hypothesis2

IL-1β source uncertainty - microglia reduction may not translate to reduced interneuron exposure

PMID:skeptic:hypothesis2

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-15 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection

Background Synthesis

The paradox that Mertk/Axl deficiency increases neuroinvasive viral susceptibility despite TAM receptors' known immunosuppressive function suggests context-dependent, cell-type-specific, or temporally regulated protective mechanisms beyond canonical immunosuppression.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris

Description: Microglial Mertk activation by GAS6 promotes efferocytosis and phagocytic clearance of virus-infected apoptotic

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of TAM Receptor Neuroprotective Hypotheses

Overview Assessment

The fundamental paradox you've identified—TAM receptors' known immunosuppressive function versus their protective role against neuroinvasive viruses—is mechanistically intriguing. However, several hypotheses conflate correlative findings with causal mechanisms, and some contain internal inconsistencies with established TAM biology. Below is my systematic critique.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Weaknesses in Evidence

**Cell-type specificity is assumed but no

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Drug Development Feasibility Assessment: TAM Receptor Neuroprotection in Neuroinvasive Viral Infection

Executive Summary

This assessment evaluates the seven hypotheses for TAM receptor-mediated neuroprotection against neuroinvasive viruses from a practical drug development standpoint—addressing target druggability, chemical matter availability, competitive landscape, and safety considerations.

Overall Strategic Assessment

The TAM receptor neuroprotection paradox presents a genuinely novel therapeutic opportunity, but with significant caveats:

| Strategic Factor | Assessment

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

TAM Receptor Neuroprotection Synthesis Analysis

Scoring Methodology

For each hypothesis, I integrate the Theorist's mechanistic proposals, the Skeptic's empirical critiques, and the Expert's drug development feasibility assessment to generate comprehensive 10-dimensional scores (0-1 scale).

Price History

7d Trend

↗

Rising

7d Momentum

▲ 2.6%

Volatility

High

0.0842

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📊	Score Update	$0.435	▼ 6.1%	market_dynamics	2026-04-14 21:36
💬	Debate Round	$0.464	▼ 15.2%	market_dynamics	2026-04-14 21:25
📄	New Evidence	$0.547	▼ 1.4%	market_dynamics	2026-04-14 19:54
📄	New Evidence	$0.555	▲ 16.1%	market_dynamics	2026-04-14 19:32
📄	New Evidence	$0.478	▲ 11.0%	market_dynamics	2026-04-14 18:43
📊	Score Update	$0.431	▲ 39.5%	market_dynamics	2026-04-14 16:36
💬	Debate Round	$0.309	▼ 11.4%	market_dynamics	2026-04-14 15:59
📊	Score Update	$0.349	▲ 16.2%	market_dynamics	2026-04-14 15:41
💬	Debate Round	$0.300		market_dynamics	2026-04-14 11:49

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (8)

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Immunological reviews (2017) · PMID:28258690

No extracted figures yet

TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration.

Disease markers (2019) · PMID:31636733

No extracted figures yet

Enhancing Tyro3 signaling ameliorates IL-1β production through STAT1 in Alzheimer's disease models.

Journal of leukocyte biology (2025) · PMID:41206011

No extracted figures yet

Paper:computational:ad_genetic_risk_loci

No extracted figures yet

Paper:computational:string_interactions

No extracted figures yet

Paper:skeptic:feasibility

No extracted figures yet

Paper:skeptic:hypothesis2

No extracted figures yet

Paper:theorist:hypothesis2

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role? — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-14-gap-pubmed-20260410-174607-708e8d91. The finding that Mertk/Axl deficiency increases viral susceptibility contradicts the established paradigm th …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.00

7.2th percentile (776 hypotheses)

Tokens Used

20,637

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

2579.62 tokens

Lower is better (baseline: 2000)

Cost per Citation

2063.70 tokens

Lower is better (baseline: 1000)

Cost per Score Point

41356.71 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.000

10% weight of efficiency score

Adjusted Composite

0.506

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for TYRO3.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TYRO3 →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (9)

GAS6 GAS6/TAM receptor complex STAT1 TAM TYRO3 h-315367de h-929f356e neuroinflammation tam_receptor_tyrosine_kinase_signaling

Related Hypotheses

IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface

Score: 0.831 | neuroinflammation

STING Antagonists as ALS Therapeutics: Drug Repurposing

Score: 0.771 | neuroinflammation

Temporal SPP1 Inhibition During Critical Windows

Score: 0.752 | neuroinflammation

PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes

Score: 0.749 | neuroinflammation

TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome

Score: 0.740 | neuroinflammation

Estimated Development

Estimated Cost

Timeline

4.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF a selective TYRO3 agonist (GAS6, 10 μg/kg, i.p.) is administered to 6-month-old 5xFAD mice for 14 consecutive days, THEN hippocampal microglial IL-1β protein levels will decrease by ≥50% relative to vehicle-treated 5xFAD controls, as measured by ELISA in fresh-frozen hippocampal tissue lysates.

pending conf: 0.52

Expected outcome: ≥50% reduction in IL-1β protein concentration (pg/mg total protein) in hippocampal tissue from GAS6-treated 5xFAD mice compared to vehicle-treated age-matched controls.

Falsified by: IL-1β levels in GAS6-treated mice are not significantly different from vehicle controls (p > 0.05, two-tailed t-test) OR IL-1β levels increase rather than decrease, indicating TYRO3 activation does not suppress microglial IL-1β production.

Method: Randomized controlled experiment using 6-month-old 5xFAD mice (n≥12 per group, equal sex distribution). GAS6 (10 μg/kg, i.p.) or vehicle (PBS) administered daily for 14 days. Terminal harvesting of hippocampal tissue at day 15, with IL-1β quantification by ELISA (R&D Systems). Blinded analysis with statistical comparison by unpaired t-test.

IF TYRO3 activation by GAS6 (10 μg/kg, i.p., 14 days) suppresses IL-1β and protects PV interneurons in 6-month-old 5xFAD mice, THEN in vivo hippocampal local field potential recordings will show ≥25% increase in gamma oscillation power (30–80 Hz) during active exploration compared to vehicle-treated 5xFAD mice.

pending conf: 0.41

Expected outcome: ≥25% increase in gamma band (30–80 Hz) power spectral density during exploratory behavior in GAS6-treated 5xFAD mice relative to vehicle controls, as assessed by chronic hippocampal LFP recordings.

Falsified by: Gamma oscillation power in GAS6-treated 5xFAD mice is unchanged (<5% change) or decreased relative to vehicle controls (p > 0.05, ANOVA with post-hoc correction), indicating that TYRO3-mediated IL-1β suppression does not translate to functional restoration of PV interneuron-mediated gamma synchronization.

Method: Randomized controlled experiment with 6-month-old 5xFAD mice (n≥10 per group) implanted with bilateral hippocampal LFP electrodes. Following 14-day GAS6 vs. vehicle treatment, 30-minute active exploration recordings are collected. Power spectral density analyzed via Welch's method; gamma band (30–80 Hz) power compared between groups using repeated-measures ANOVA, with experimenter blinded to treatment allocation.

Knowledge Subgraph (8 edges)

Mechanism Pathway for TYRO3

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_315367de["h-315367de"] -->|targets| TYRO3["TYRO3"]
    TYRO3_1["TYRO3"] -->|associated with| neuroinflammation["neuroinflammation"]
    TYRO3_2["TYRO3"] -->|involved in| tam_receptor_tyrosine_kin["tam_receptor_tyrosine_kinase_signaling"]
    TYRO3_3["TYRO3"] -->|co associated with| STAT1["STAT1"]
    style h_315367de fill:#4fc3f7,stroke:#333,color:#000
    style TYRO3 fill:#ce93d8,stroke:#333,color:#000
    style TYRO3_1 fill:#ce93d8,stroke:#333,color:#000
    style neuroinflammation fill:#ef5350,stroke:#333,color:#000
    style TYRO3_2 fill:#ce93d8,stroke:#333,color:#000
    style tam_receptor_tyrosine_kin fill:#81c784,stroke:#333,color:#000
    style TYRO3_3 fill:#ce93d8,stroke:#333,color:#000
    style STAT1 fill:#ce93d8,stroke:#333,color:#000

Predicted Protein Structure

🔮 TYRO3 — AlphaFold Prediction H3BPR7 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

neuroinflammation | 2026-04-14 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (1)

GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neur

Score: 0.51 · GAS6/TAM receptor complex

→ View all analysis hypotheses

TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 5

✗ Opposing Evidence 5

Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection

Background Synthesis

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris

Critical Evaluation of TAM Receptor Neuroprotective Hypotheses

Overview Assessment

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Weaknesses in Evidence

Drug Development Feasibility Assessment: TAM Receptor Neuroprotection in Neuroinvasive Viral Infection

Executive Summary

Overall Strategic Assessment

TAM Receptor Neuroprotection Synthesis Analysis

Scoring Methodology

Price History

Clinical Trials (0)

📚 Cited Papers (8)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (1)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (9)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (8 edges)

associated with (2)

co associated with (3)

involved in (1)

targets (2)

Mechanism Pathway for TYRO3

Predicted Protein Structure

Source Analysis

Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

Community Feedback

Same Analysis (1)